All In Biotech

NDA 216196 · Agios Pharms INC

Pyrukynd

Mitapivat Sulfate · Oral · Pyruvate Kinase Activator

NovelPriority reviewOrphan

CDER novel approval, Feb 17, 2022: To treat hemolytic anemia in pyruvate kinase deficiency

Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Feb 17, 2022

Approved uses

2

Original approval plus efficacy supplements

Registered trials

29

11 Phase 3, 3 recruiting

FAERS reports

1,331

199 serious, 7 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: HEPATOCELLULAR INJURY AQVESME can cause serious hepatocellular injury. Measure liver laboratory tests (ALT, AST, alkaline phosphatase, and total bilirubin with fractionation) at baseline and every 4 weeks for 24 weeks and then as clinically indicated. Avoid use of AQVESME in patients with cirrhosis. Discontinue AQVESME if hepatic injury is suspected [see Warnings and Precautions ( 5.1 )] . Because of the risk of hepatocellular injury, AQVESME is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the AQVESME REMS [see Warnings and Precautions ( 5.2 )] . WARNING: HEPATOCELLULAR INJURY See full prescribing information for complete boxed warning. AQVESME can cause serious hepatocellular injury. Measure liver laboratory tests (ALT, AST, alkaline phosphatase, and total bilirubin with fractionation) at baseline and every 4 weeks...

What it is approved for

From the label in effect Aug 27, 2026.

AQVESME is indicated for the treatment of anemia in adults with alpha- or beta-thalassemia. AQVESME is a pyruvate kinase activator indicated for the treatment of anemia in adults with alpha- or beta-thalassemia. ( 1.1 )

Mechanism: Mitapivat is a pyruvate kinase activator that acts by allosterically binding to the pyruvate kinase tetramer and increasing pyruvate kinase (PK) activity. Imbalances in globin chain production during erythropoiesis result in increased oxidative stress, which leads to ineffective erythropoiesis and hemolysis. In nonclinical models of beta-thalassemia, mitapivat improved energy homeostasis, RBC longevity, ineffective erythropoiesis, and hemolysis by increasing PK activity.

Therapeutic areas: Hematology and blood cancers · Rare and genetic disease

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • PYRUKYND · MITAPIVAT SULFATE EQ 20MG BASE · TABLET, ORAL · Prescription
  • PYRUKYND · MITAPIVAT SULFATE EQ 50MG BASE · TABLET, ORAL · Prescription
  • PYRUKYND · MITAPIVAT SULFATE EQ 5MG BASE · TABLET, ORAL · Prescription
  • AQVESME · MITAPIVAT SULFATE EQ 100MG BASE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Mitapivat" as an intervention, any sponsor and status, largest first.

All 29 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • haemoglobin decreased230
  • product dose omission issue197
  • headache173
  • fatigue159
  • insomnia124
  • off label use123
  • nausea86
  • arthralgia82
  • drug ineffective76
  • back pain64
  • dizziness56
  • asthenia52

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2022119
2023182
2024192
2025217
2026621

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Pyrukynd (Mitapivat Sulfate)

2024 spending

$6.0M

Beneficiaries

26

226 claims

Per beneficiary

$230,488

$467.38 per unit

View as table
YearSpending
2020$0
2021$0
2022$1,573,075
2023$4,466,375
2024$5,992,677

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 25 on PubMed

Sponsor: Agios Pharms INC · Also marketed as Aqvesme

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.